Erectile Dysfunction Drugs: A Global Strategic Business Report
San Jose, CA (PRWEB) March 24, 2010
Erectile Dysfunction (ED) is condition in which a man is not able to achieve and maintain adequate erection for a satisfactory sexual intercourse. It affects the lives of many middle-aged men as well as their partners across the world. Erectile dysfunction can also be a sign of an emotional or physical problem that needs treatment. Earlier, ED was considered a taboo subject and a very small percentage of men would actively seek treatment. However, over a period of time, more men have started seeking help. Moreover, doctors are gaining a better understanding of the physiological and psychological causes of ED, which is enabling them to develop advanced treatments.
The United States and Europe dominate the world erectile dysfunction drugs market as stated by the new market research report on erectile dysfunction drugs market. With a rise in the dependence on medicines that causes side effects such as erectile dysfunction, increase in the baby-boomer population, and various other co-morbid groups including depression, diabetic, and cardiovascular patients, the US market for erectile dysfunction drugs witnessed a significant expansion. These numbers are expected to experience continuous growth in the country, paving way for a higher demand as well as steady revenues. Due to the convenience and effectiveness associated with the prescription oral medications, they continue to remain the most common form of treatment for erectile dysfunction in Europe. The launch of novel topical, over-the-counter and prescription drugs would benefit in expanding the ED market, as well as paving way for the development of advanced oral ED medications.
There are several companies involved in the development of therapeutics for the treatment of ED. While the treatment options differ between oral therapies, implants, injectibles, and topical treatments, oral medications continue to dominate the ED drug market worldwide. Key players profiled in the report include Abbott Laboratories, Eli Lilly and Company Inc., F. Hoffmann-La Roche Inc., GlaxoSmithKline plc, Nexmed Inc., Pfizer Inc., Sanofi-aventis SA, Vivus Inc., and Warner Chilcott Limited.
The report titled "Erectile Dysfunction Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, product overview, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Canada, Japan, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Erectile_Dysfunction_Drugs_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/